Bio-Techne (TECH) director Baumgartner received 2,750 shares
Director Robert Baumgartner was granted 2,750 shares at $0, lifting direct holdings 5% to 59,634 shares; routine director compensation.
Insider transactions reported
Robert V Baumgartner (director at Bio-Techne Corp, TECH) reported that they received 2,750 shares on Oct 29, 2026. After these transactions the filing shows 59,634 shares held directly.
- Reporting person
- Baumgartner Robert V
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 29, 2026 | Grant or award (A) | Common Stock | +2,750 | - | - | 59,634 direct |
Holdings before and after
- Common Stock: 56,884 to 59,634 direct
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Baumgartner report in this TECH Form 4?
Robert V Baumgartner (director at Bio-Techne Corp, TECH) reported that they received 2,750 shares on Oct 29, 2026. After these transactions the filing shows 59,634 shares held directly.
How many TECH shares does Baumgartner hold after this filing?
The filing shows 59,634 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for TECH
Across the 26 sessions after earlier TECH headlines, the stock closed higher 14 times and lower 12 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TECH | SPY |
|---|---|---|---|
| Oct 8, 2026 | Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development | -0.1% | -0.4% |
| Sep 23, 2026 | Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany | -0.0% | -0.7% |
| Sep 22, 2026 | Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration | +0.1% | -0.0% |
| Sep 1, 2026 | Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals | -0.2% | -0.7% |
| Aug 13, 2026 | Bio-Techne downgraded by Wells Fargo with a new price targetand 1 other headline that session | -0.1% | +0.7% |
| Aug 12, 2026 | Bio-Techne Releases Fourth Quarter Fiscal 2026 Resultsand 1 other headline that session | +0.1% | +0.3% |
Earlier insider filings at TECH
- Sep 30, 2026Director Higgins John L converted options into 15,940 shares and covered exercise/tax liability with 5,562 shares, increasing direct ownership by 16% to 77,254 units (SEC Form 4)
- Sep 24, 2026Director Baumgartner Robert V converted options into 15,940 shares and covered exercise/tax liability with 5,559 shares, increasing direct ownership by 22% to 56,884 units (SEC Form 4)
- Aug 19, 2026SEC Form 4 filed by SVP - General Counsel Bohnen Shane
- Aug 19, 2026SEC Form 4 filed by Chief Executive Officer Kelderman Kim
- Aug 19, 2026SEC Form 4 filed by CFO Hippel James
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Follow TECH and get a push notification the moment its next story breaks.